Formulation development and evaluation of controlled release matrix tablets of glibenclamide

Abstract

The present study aimed to formulate and evaluate the controlled-release matrix tablets of Glibenclamide which is an antidiabetic drug that belongs to the second-generation oral hypoglycemics. Matrix tablets were prepared by three different polymers as sustained-release agents, using Glibenclamide as a model drug. Three polymers were selected for this study- HPMC K 15, HPMC K 100, and EC in different drug: polymer ratios. The drug was identified by FTIR spectroscopic method. The pre-compression and post-compression parameters of all formulations were found to be within acceptable limits. The release rate of Glibenclamide from matrix tablets was studied using the USP Dissolution Testing Apparatus type-I (Basket method). The formulation F6 which contained EC 50mg showed a maximum release of 99.28% in 24 hrs and revealed that EC was more effective in sustaining the drug release therefore formulation F6 was selected as the optimized formulation. The in-vitro release data of optimized formulation was fit into various kinetic models, among the different model's data of in-vitro release of best fit into Zero order kinetic model. The formulation best fit the Higuchi model and showed that drug release from the prepared matrix tablets occurs via a diffusion process.